<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534350</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-218-1797</org_study_id>
    <secondary_id>2015-002287-16</secondary_id>
    <nct_id>NCT02534350</nct_id>
  </id_info>
  <brief_title>Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection</brief_title>
  <acronym>RSVAdultLungTx</acronym>
  <official_title>A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of presatovir on nasal respiratory syncytial virus (RSV)
      viral load in RSV-positive lung transplant (LT) recipients with acute respiratory symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2015</start_date>
  <completion_date type="Actual">September 27, 2017</completion_date>
  <primary_completion_date type="Actual">February 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-Weighted Average Change in log10 Viral Load from Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>This co-primary endpoint will measure the time-weighted average change in viral load from Day 1/baseline through Day 7 among participants in the Full Analysis Set. The time-weighted average change (DAVG) provides the average viral burden in change from baseline during the time period of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-Weighted Average Change in log10 Viral Load from Day 1/Baseline Through Day 7 in a Subset of Participants in the Full Analysis Set Whose Duration of RSV Symptoms Prior to the First Dose of Study Drug is ≤ Median</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>This co-primary endpoint will measure the time-weighted average change in viral load from Day 1/baseline through Day 7 in a subset of participants in the Full Analysis Set whose duration of RSV symptoms prior to the first dose of study drug is ≤ median.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-Weighted Average Change in FLU-PRO Score from Day 1/Baseline Through Day 7</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>FLU-PRO score will be measured using a self-administered questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Study Baseline in FEV1% Predicted Value at Day 28/End of Study</measure>
    <time_frame>Baseline; Day 28</time_frame>
    <description>FEV1 is defined as forced expiratory volume in the first second.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Respiratory Syncytial Virus (RSV)</condition>
  <arm_group>
    <arm_group_label>Presatovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Presatovir for a total of 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Presatovir placebo for a total of 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Presatovir</intervention_name>
    <description>Presatovir tablets administered orally once daily</description>
    <arm_group_label>Presatovir</arm_group_label>
    <other_name>GS-5806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Presatovir placebo tablets administered orally once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Received a LT (single or double) or heart/lung transplant &gt; 90 days prior to screening

          -  Confirmed to be RSV-positive by local polymerase chain reaction (PCR) testing
             (starting from when the upper or lower respiratory tract sample is obtained) ≤ 7 days
             prior to study drug administration on Day 1/baseline

          -  New onset or acute worsening of at least 1 of the following respiratory symptoms ≤ 7
             days prior to study drug administration: nasal congestion, earache, runny nose, cough,
             sore throat, shortness of breath, or wheezing

          -  An informed consent document signed and dated by the individual

          -  A negative urine or serum pregnancy test for females of childbearing potential

          -  Agreement from males and females of childbearing potential to use contraception

          -  Ability and willingness to complete necessary study procedures

        Key Exclusion Criteria:

        Related to concomitant or previous medication use:

          -  Use of the following lympholytic treatment: anti-thymocyte globulin (ATG), &lt; 3 months;
             anti-lymphoblast globulin (ALG), &lt; 3 months; muromonab-CD3 (OKT3), &lt; 3 months;
             rituximab &lt; 6 months; alemtuzumab &lt; 9 months

        Related to transplant history:

          -  Recipient of any other organ transplant prior to screening, with the exception of a LT
             (single or double) or heart/lung transplant

          -  Recipient of a hematopoietic cell transplant at any time

          -  Presence of BOS Stage 3 at screening defined as a FEV1 of 50% or less of baseline

        Related to medical condition at screening:

          -  Respiratory failure requiring invasive mechanical ventilation

          -  Evidence of shock requiring vasopressors

          -  Known viral coinfection (including but not limited to influenza, metapneumovirus,
             human rhinovirus, parainfluenza, cytomegalovirus, or coronavirus) in the upper or
             lower respiratory tract ≤ 14 days prior to screening unless discussed with the medical
             monitor and deemed acceptable

          -  Active systemic infection or infectious pneumonia of any etiology (ie, bacterial,
             viral [other than RSV] or fungal), including aspiration pneumonia, that is considered
             clinically significant by the investigator unless discussed with the medical monitor
             and deemed acceptable

          -  Pregnant or lactating females

          -  Evidence of recent and rapidly deteriorating lung function, occurring before the onset
             of the current viral respiratory infection

        Related to allergies:

          -  Known hypersensitivity or allergy to the study drug, its metabolites, or formulation
             excipients (microcrystalline cellulose, mannitol, croscarmellose sodium, magnesium
             stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol and talc)

          -  History of hypersensitivity, anaphylactic reaction, Stevens-Johnson Syndrome, or toxic
             epidermal necrolysis response to sulfa drugs

        Related to laboratory values:

          -  Clinically significant kidney dysfunction

          -  Clinically significant liver function test abnormalities

          -  Clinically significant elevations in total bilirubin (TB), as determined by the
             investigator

        Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <disposition_first_submitted>February 2, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 2, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 8, 2018</disposition_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus (RSV)</keyword>
  <keyword>Antiviral</keyword>
  <keyword>Lung Transplant</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

